QUMAS, a leading provider of quality management and regulatory affairs solutions, today announced that ImmunoGen, Inc has selected QUMAS DocCompliance™ and ProcessCompliance™ for its regulatory- and manufacturing-related compliance initiatives and document management requirements. ImmunoGen develops targeted anticancer compounds, and manufactures materials for use in its own clinical trial programs and those of its partners.

"We are pleased that ImmunoGen chose QUMAS to address their quality and manufacturing compliance management initiatives," said Kevin O'Leary, CEO at QUMAS.

QUMAS DocCompliance, the cornerstone of the QUMAS Enterprise Management Suite, enables organizations to create, manage and securely store all content, reports and records. QUMAS ProcessCompliance is the premier application of its type, delivering pre-configured, built-in best practices for the management of a wide range of processes, including; CAPA, planned and unplanned deviations, audits, customer complaints, and multi-site change control.

About QUMAS
QUMAS is a leading developer of enterprise compliance management solutions designed to help life sciences organizations meet industry and government standards for 21 CFR Part 11, cGxP, Quality, Regulatory Affairs and Clinical Operations. With over a decade of experience, QUMAS is helping companies accelerate business processes, reduce costs and improve quality. From content lifecycle management, business process and change management to reporting and analysis, QUMAS Compliance Suite is successfully enabling global life science organizations to proactively manage their regulated content and processes in a secure and compliant way.

For more information visit http://www.qumas.com.